Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial
- PMID: 22452895
- DOI: 10.1016/S1470-2045(12)70086-4
Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial
Abstract
Background: Afatinib is an irreversible ErbB-family blocker with preclinical activity in non-small-cell lung cancer (NSCLC) with EGFR mutations. We aimed to assess the efficacy of afatinib in patients with lung adenocarcinoma and EGFR mutations.
Methods: In this phase 2 study, we enrolled patients from 30 centres in Taiwan and the USA with lung adenocarcinoma (stage IIIb with pleural effusion or stage IV) with EGFR mutations, who had no more than one previous chemotherapy regimen for advanced disease, an Eastern Cooperative Oncology Group performance status of 0-2, and no previous treatment with EGFR tyrosine-kinase inhibitors. We tested two afatinib starting doses: 50 mg daily and subsequently 40 mg daily, introduced to establish whether tolerability could be improved with retention of anti-tumour activity. The primary endpoint was the proportion of patients with a confirmed objective response (complete response or partial response), on the basis of Response Evaluation Criteria in Solid Tumors 1.0 (independent review). This study is registered with ClinicalTrials.gov, number NCT00525148.
Findings: 129 patients were treated with afatinib, 99 with a starting dose of 50 mg and 30 with a starting dose of 40 mg. 79 (61%) of 129 patients had an objective response (two complete responses, 77 partial responses). 70 (66%) of the 106 patients with the two common activating EGFR mutations (deletion 19 or L858R) had an objective response, as did nine (39%) of 23 patients with less common mutations. Similar proportions of patients had an objective response when analysed by starting dose (18 [60%] of 30 patients at 40 mg vs 61 [62%] of 99 patients at 50 mg). Of the two most common adverse events (diarrhoea and rash or acne), grade 3 events were more common in patients receiving a 50 mg starting dose (22 [22%] of 99 patients for diarrhoea and 28 [28%] of 99 patients for rash or acne) than they were in those receiving a 40 mg starting dose (two [7%] of 30 patients for both diarrhoea and rash or acne); possibly treatment-related serious adverse events were also less common in patients receiving a 40 mg starting dose (two of 30 patients vs 14 of 99 patients). We recorded one possibly drug-related death (interstitial lung disease).
Interpretation: Afatinib shows activity in the treatment of patients with advanced lung adenocarcinoma with EGFR mutations, especially in patients with deletion 19 or L858R mutations. The efficacy of afatinib 40 mg should be compared with chemotherapy or other EGFR tyrosine-kinase inhibitors in EGFR-mutation-positive NSCLC.
Funding: Boehringer Ingelheim Inc.
Copyright © 2012 Elsevier Ltd. All rights reserved.
Comment in
-
A new generation of EGFR tyrosine-kinase inhibitors in NSCLC.Lancet Oncol. 2012 May;13(5):442-3. doi: 10.1016/S1470-2045(12)70124-9. Epub 2012 Mar 26. Lancet Oncol. 2012. PMID: 22452893 No abstract available.
Similar articles
-
Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial.Lancet Oncol. 2012 May;13(5):528-38. doi: 10.1016/S1470-2045(12)70087-6. Epub 2012 Mar 26. Lancet Oncol. 2012. PMID: 22452896 Clinical Trial.
-
Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial.Lancet Oncol. 2015 Aug;16(8):897-907. doi: 10.1016/S1470-2045(15)00006-6. Epub 2015 Jul 5. Lancet Oncol. 2015. PMID: 26156651 Clinical Trial.
-
LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both.J Clin Oncol. 2013 Sep 20;31(27):3335-41. doi: 10.1200/JCO.2012.45.0981. Epub 2013 Jul 1. J Clin Oncol. 2013. PMID: 23816963 Clinical Trial.
-
Afatinib: a review of its use in the treatment of advanced non-small cell lung cancer.Drugs. 2014 Feb;74(2):207-21. doi: 10.1007/s40265-013-0170-8. Drugs. 2014. PMID: 24435321 Review.
-
Afatinib: An overview of its clinical development in non-small-cell lung cancer and other tumors.Crit Rev Oncol Hematol. 2016 Jan;97:143-51. doi: 10.1016/j.critrevonc.2015.08.016. Epub 2015 Aug 12. Crit Rev Oncol Hematol. 2016. PMID: 26318094 Review.
Cited by
-
"ACHILLES" Heel No More? Afatinib at 40 Mg Once Daily is Superior to Platinum-Based Chemotherapy in EGFR Uncommon (G719X, S768I, and L861Q) Mutations (ACHILLES/TORG1834).Lung Cancer (Auckl). 2024 May 18;15:69-73. doi: 10.2147/LCTT.S461758. eCollection 2024. Lung Cancer (Auckl). 2024. PMID: 38784059 Free PMC article.
-
Major adverse cardiovascular events in advanced-stage lung cancer: a multicenter cohort study.Ther Adv Med Oncol. 2024 Jan 18;16:17588359231221907. doi: 10.1177/17588359231221907. eCollection 2024. Ther Adv Med Oncol. 2024. PMID: 38249337 Free PMC article.
-
Treatment of Non-Small Cell Lung Cancer with Atypical EGFR Mutations.Curr Treat Options Oncol. 2023 Dec;24(12):1802-1814. doi: 10.1007/s11864-023-01159-z. Epub 2023 Dec 14. Curr Treat Options Oncol. 2023. PMID: 38095779 Review.
-
Discovery of New Pyrrolo[2,3-d]pyrimidine Derivatives as Potential Multi-Targeted Kinase Inhibitors and Apoptosis Inducers.Pharmaceuticals (Basel). 2023 Sep 19;16(9):1324. doi: 10.3390/ph16091324. Pharmaceuticals (Basel). 2023. PMID: 37765132 Free PMC article.
-
Real-World Response and Outcomes in Patients With NSCLC With EGFR Exon 20 Insertion Mutations.JTO Clin Res Rep. 2023 Aug 16;4(10):100558. doi: 10.1016/j.jtocrr.2023.100558. eCollection 2023 Oct. JTO Clin Res Rep. 2023. PMID: 37744306 Free PMC article.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous